Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9NO3 |
Molecular Weight | 179.173 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)C(=NCC(=O)O)O
InChI
InChIKey=QIAFMBKCNZACKA-UHFFFAOYSA-N
InChI=1S/C9H9NO3/c11-8(12)6-10-9(13)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)(H,11,12)
Molecular Formula | C9H9NO3 |
Molecular Weight | 179.173 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19891605 and https://www.medicines.org.uk/emc/medicine/7597
Curator's Comment:: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19891605 and https://www.medicines.org.uk/emc/medicine/7597
Hippuric Acid is an acyl glycine produced by the conjugation of benzoic acid and glycine, found as a normal component in urine as a metabolite of aromatic compounds from food. Increased urine hippuric acid content may have antibacterial effects. Hippuric Acid is used therapeutically in the form of its salts (hippurates of calcium and ammonium). It is an ingredient of FDA-approved drug Hiprex (methenamine hippurate tablets USP). Each yellow capsule-shaped tablet of Hiprex contains 1 g Methenamine Hippurate which is the Hippuric Acid Salt of Methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients. Hiprex (methenamine hippurate tablets USP) has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against E. coli, enterococci and staphylococci. Enterobacter aerogenes is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such as Proteus and Pseudomonas to be inhibited. Hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1641347 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11815391 |
20.0 µM [IC50] | ||
Target ID: CHEMBL1641348 Sources: http://www.ncbi.nlm.nih.gov/pubmed/14675047 |
30.8 µM [Ki] | ||
Target ID: Bacterial growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3895402 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | HIPREX Approved UseHIPREX is indicated for prophylactic or suppressive treatment of frequently recurring urinary
tract infections when long-term therapy is considered necessary. This drug should only be used
after eradication of the infection by other appropriate antimicrobial agents. Launch Date2.10988794E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. | 1975 May |
|
[Quantitative assay of metabolic rate of para-aminobenzoic acid combining glycine for the assessment of rabbit liver function]. | 2001 Aug |
|
Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. | 2001 Dec |
|
Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. | 2001 Oct |
|
Gardnerella vaginalis isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems. | 2001 Oct 1 |
|
Fast homogeneous assay for plasma procarboxypeptidase U. | 2001 Sep |
|
Synthesis of some new quinoline derivatives: new routes to synthesize polysubstituted 2(1H)-quinolone derivatives. | 2001 Sep-Oct |
|
Effect of anticoagulants in colorimetric assay for basic carboxypeptidases. | 2002 |
|
Proton nuclear magnetic resonance spectral profiles of urine from children and adolescents with type 1 diabetes. | 2002 |
|
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. | 2002 Apr |
|
Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo. | 2002 Apr |
|
Sister chromatid exchanges and micronuclei in peripheral lymphocytes of shoe factory workers exposed to solvents. | 2002 Apr |
|
Mapping of local renal blood flow with PET and H(2)(15)O. | 2002 Apr |
|
Effect of protein-bound uraemic toxins on the thermodynamic characteristics of human albumin. | 2002 Apr 1 |
|
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. | 2002 Aug |
|
Validated method for quantitation of biomarkers for benzene and its alkylated analogues in urine. | 2002 Jul 15 |
|
The effect of cigarette smoking on urinary hippuric acid concentration in Thai workers with occupational exposure to toluene. | 2002 Jun |
|
Urinary benzylmercapturic acid as a marker of occupational exposure to toluene. | 2002 Jun |
|
Biochemical function of the donor liver in living related liver transplantation. | 2002 Mar |
|
Improved method for direct high-performance liquid chromatography assay of angiotensin-converting enzyme-catalyzed reactions. | 2002 Mar 15 |
|
Helicobacter muricola sp. nov., a novel Helicobacter species isolated from the ceca and feces of Korean wild mouse (Mus musculus molossinus). | 2002 Mar 19 |
|
Toluene metabolites as biological indicators of exposure. | 2002 Mar 24 |
|
Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. | 2002 May |
|
Improved paclitaxel and baccatin III production in suspension cultures of Taxus media. | 2002 May-Jun |
|
Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. | 2002 Nov |
|
Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. | 2002 Nov |
|
Peptides with angiotensin I-converting enzyme (ACE) inhibitory activity from defibrinated, hydrolyzed bovine plasma. | 2002 Nov 20 |
|
Simultaneous determination of styrene, toluene, and xylene metabolites in urine by gas chromatography/mass spectrometry. | 2002 Oct |
|
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. | 2002 Oct |
|
Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. | 2002 Oct 23 |
|
High levels of hippuric acid in the urine of Thai press workers. | 2002 Sep |
|
Effect of intestinal microflora on the urinary metabolic profile of rats: a (1)H-nuclear magnetic resonance spectroscopy study. | 2002 Sep |
|
Bioactivation of benzylamine to reactive intermediates in rodents: formation of glutathione, glutamate, and peptide conjugates. | 2002 Sep |
|
Simultaneous detection of hippuric acid and methylhippuric acid in urine by Empore disk and gas chromatography-mass spectrometry. | 2002 Sep 5 |
|
Gender differences in the metabolism of benzene, toluene and trichloroethylene in rat with special reference to certain biochemical parameters. | 2003 Apr |
|
Moment analysis of metabolic heterogeneity: conjugation of benzoate with glycine in rat liver studied by multiple indicator dilution technique. | 2003 Apr |
|
Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. | 2003 Apr |
|
Palladium-catalyzed asymmetric addition of pronucleophiles to allenes. | 2003 Apr 16 |
|
Acid-base status of critically ill patients with acute renal failure: analysis based on Stewart-Figge methodology. | 2003 Aug |
|
Detection of carboxylic acids and inhibition of hippuric acid formation in rats treated with 3-butene-1,2-diol, a major metabolite of 1,3-butadiene. | 2003 Aug |
|
Kinetic study of angiotensin converting enzyme activity by capillary electrophoresis after in-line reaction at the capillary inlet. | 2003 Feb 7 |
|
Analysis method of the angiotensin-I converting enzyme inhibitory activity based on micellar electrokinetic chromatography. | 2003 Jan |
|
Expression and characterization of frog peptidylglycine alpha-hydroxylating monooxygenase. | 2003 Jan |
|
Glycine conjugation of para-aminobenzoic acid (PABA): a pilot study of a novel prognostic test in acute liver failure in children. | 2003 Jan |
|
Solvent ototoxicity in the rat and guinea pig. | 2003 Jan-Feb |
|
Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative. | 2003 Jun 16 |
|
Rapid detection and identification of Brachyspira aalborgi from rectal biopsies and faeces of a patient. | 2003 Mar |
|
Alteration of local ACE activity and vascular responsiveness during development of 2K1C renovascular hypertension. | 2003 Mar |
|
Comparison of the BAX System with a multiplex PCR method for simultaneous detection and identification of Campylobacter jejuni and Campylobacter coli in environmental samples. | 2003 Nov 1 |
|
Human urine certified reference material CZ 6009: creatinine, styrene metabolites (mandelic acid and phenylglyoxylic acid). | 2004 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/hiprex.html
1 tablet (1.0 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1.0 g) twice daily (morning and night) for pediatric patients 6 to 12 years of age. Since the antibacterial activity of Hiprex is greater in acid urine, restriction of alkalinizing foods and medications is desirable.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11815391
Hippuric acid inhibits PAH uptake in OAT1-expressing proximal tubular cells OK cells with IC50 20uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 05:01:02 UTC 2021
by
admin
on
Sat Jun 26 05:01:02 UTC 2021
|
Record UNII |
TE0865N2ET
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C255
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
||
|
LOINC |
75069-5
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TE0865N2ET
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
M6023
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | Merck Index | ||
|
207-806-3
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
495-69-2
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
464
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
495-69-2
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
C87277
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
SUB33142
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
1923619
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
C030514
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY | |||
|
HIPPURIC ACID
Created by
admin on Sat Jun 26 05:01:02 UTC 2021 , Edited by admin on Sat Jun 26 05:01:02 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE | |||
|
PARENT -> METABOLITE INACTIVE |
IN-VIVO
URINE
|
||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |